ClinicalTrials.gg

Program

cenerimod

Also written as “Cenerimod”, “Cenerimod 0.5 mg” and “Cenerimod 4 mg”.

Its studies are mostly in Lupus Erythematosus, Systemic · Lupus Nephritis · Renal Insufficiency, led by Viatris.

Furthest: phase 3, since Dec 5, 202214 company-led studies, 5 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatris145 open or runningphase 3since Dec 5, 2022May 14, 2015Dec 31, 2026phase 3 · NCT05672576

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 14, 2015First study: phase 2 study in Lupus Erythematosus, SystemicFirst studyNCT02472795 · 105 enrolled · United States, Belarus, Bulgaria and more
  2. Jun 17, 2015Phase 1 study in Healthy SubjectsNCT02479204 · 10 enrolled · France
  3. Sep 13, 2016Phase 1 study in Healthy SubjectsNCT02914223 · 6 enrolled · Netherlands
  4. Nov 12, 2018Phase 2 study in Lupus Erythematosus, SystemicNCT03742037 · 427 enrolled · United States, Bulgaria, Chile and more
  5. Aug 8, 2019Phase 1 study in Healthy VolunteersNCT04052360 · 20 enrolled · United States
  6. Jan 29, 2020Phase 1 study in Healthy SubjectsNCT04255277 · 97 enrolled · France
  7. Mar 16, 2021Phase 1 study in HealthyNCT04819464 · 24 enrolled · Hungary, Portugal
  8. Aug 3, 2021Phase 1 study in Renal InsufficiencyNCT05004311 · 16 enrolled · Portugal
  9. Dec 5, 2022Phase 3 study in Lupus Erythematosus, SystemicNCT05648500 · 470 enrolled · United States, Argentina, Brazil and more
  10. Jan 3, 2023Phase 3 study in Lupus Erythematosus, SystemicNCT05672576 · 451 enrolled · United States, Chile, Czechia and more
  11. Jun 20, 2024Phase 3 study in Lupus Erythematosus, SystemicNCT06475742 · 680 planned · United States, Argentina, Brazil and more
  12. Sep 23, 2025Phase 3 study in Lupus NephritisNCT07201129 · 300 planned · United States
  13. Nov 17, 2025Phase 1 study in Healthy SubjectsNCT07301723 · 6 enrolled · Netherlands
  14. Nov 17, 2025Phase 2 study in Lupus Erythematosus, SystemicNCT07266090 · 15 enrolled · China

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT05672576
  2. Mar 31, 2027Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT05648500
  3. Oct 8, 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07266090
  4. Aug 2029Primary completion: phase 3 study in Lupus NephritisNCT07201129

TargetBeta

S1PR1 →read by rule
“Sphingosine 1-phosphate receptor Edg-1 modulator”ChEMBL 37, by rule

Other programs on S1PR1

ProgramCompanyFurthest phaseStudies
fingolimodruleNovartisphase 455
etrasimodrulePfizerphase 321
ponesimodruleJohnson & Johnsonphase 316
mocravimodruleNovartisphase 35

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07301723Healthy Subjects · Netherlands1CompletedMar 18, 20266
NCT07266090Lupus Erythematosus, Systemic · China2Active, not recruitingOct 8, 202715
NCT07201129Lupus Nephritis · United States3RecruitingAug 2029300
NCT06475742Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more3By invitationSep 2032680
NCT05672576Lupus Erythematosus, Systemic · United States, Chile, Czechia and more3Active, not recruitingDec 31, 2026451
NCT05648500Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more3Active, not recruitingMar 31, 2027470
NCT05004311Renal Insufficiency · Portugal1CompletedJul 27, 202316
NCT04819464Healthy · Hungary, Portugal1CompletedAug 18, 202424
NCT04255277Healthy Subjects · France1CompletedSep 14, 202197
NCT04052360Healthy Volunteers · United States1CompletedOct 29, 201920
NCT03742037Lupus Erythematosus, Systemic · United States, Bulgaria, Chile and more2CompletedAug 31, 2021427
NCT02914223Healthy Subjects · Netherlands1CompletedDec 1, 20166
NCT02479204Healthy Subjects · France1TerminatedMay 1, 201610
NCT02472795Lupus Erythematosus, Systemic · United States, Belarus, Bulgaria and more2CompletedJan 23, 2017105

How it is read

Names in the registry

  • “Cenerimod”, 9 entries
  • “Cenerimod 0.5 mg”, 2 entries
  • “Cenerimod 4 mg”, 2 entries
  • “Cenerimod 1 mg”, 1 entry
  • “Cenerimod 2 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.